Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Sustained efficacy along with improvements in disease activity score 28 (DAS 28) and patient (Pt)-reported outcomes (PROs) with abatacept (Aba) in rheumatoid arthritis (RA) pts with an inadequate response to anti-tumor necrosis factor (TNF) therapy: The long-term extension (LTE) of the attain trial Annual Meeting of the British-Society-of-Rheumatology Dougados, M., Schiff, M., Luggen, M., Becker, J. C., Aranda, R., Li, T., McCann, T., Schmidely, N., LeBars, M., Sibilia, J., Genovese, M. C. OXFORD UNIV PRESS. 2007: I99–I99
View details for Web of Science ID 000250724200309